In a groundbreaking announcement, the FDA has expanded the indication of efgartigimod alfa and hyaluronidase-qvfc (Vyvgart Hytrulo) to include treatment for adults suffering from chronic inflammatory demyelinating polyneuropathy (CIDP). This decision marks a significant milestone in the field of CIDP treatment, providing patients and healthcare providers with a new, safe, and effective treatment option. CIDP
Health
The LENS trial has provided valuable insights into the potential benefits of using fenofibrate as a treatment for early diabetic retinopathy among patients with diabetes. The findings of this study have significant implications for the management of this common and debilitating complication of diabetes. The results of the LENS trial demonstrated that fenofibrate reduced the
The drug sample that I received for testing contained a variety of dangerous substances, including multiple nitazenes, fentanyl analogues, xylazine, diphenhydramine, caffeine, and medetomidine. It was the presence of medetomidine that particularly caught my attention. This specimen had been sent to me after a patient experienced an overdose, and the preliminary report indicated a complex
The presentation by Roy Herbst, MD, PhD, from Yale Cancer Center highlighted the significant advancements in the treatment of EGFR-mutated non-small cell lung cancer (NSCLC) with osimertinib. The discussion focused on the outcomes from the LAURA and ADAURA trials, particularly the improvements in progression-free survival (PFS) in patients with stage III disease. This is a
The analysis of medical records involving 88,000 individuals with Systemic Lupus Erythematosus (SLE) has revealed interesting findings related to the use of metformin in these patients. The study, conducted by Yurilu A. Gonzalez Moret, MD, and colleagues at Thomas Jefferson University in Philadelphia, suggests that SLE patients who were taking metformin had lower rates of
Rheumatoid arthritis (RA) is a chronic inflammatory disorder that not only affects the joints but also poses a risk for cardiovascular complications. Recent research conducted by Katherine P. Liao, MD, MPH, and colleagues at Brigham and Women’s Hospital in Boston suggests that regular high-sensitivity cardiac troponin T (hs-cTnT) testing may hold significant value in assessing
A recent study highlighted the concerning reality of lost opportunities in treating drug overdose survivors covered by the Medicare program. The study showcased the challenges associated with managing chronic pain and addiction, painting a bleak picture of the current state of treatment for overdose survivors. Despite recommendations from experts in the field, overdose survivors on
In a groundbreaking move, the FDA has approved two new immunotherapy-chemotherapy options for patients with primary advanced or recurrent endometrial cancer. One of the options is the PD-1-directed immune checkpoint inhibitor pembrolizumab, also known as Keytruda, which is now approved in combination with carboplatin and paclitaxel for patients with either mismatch repair (MMR)-deficient or MMR-proficient
The statement made by Dean Ornish, MD, regarding lifestyle intervention and Alzheimer’s disease is quite bold. While it is true that a healthy lifestyle can have positive effects on overall health, claiming that the only side effects are good ones seems like an oversimplification. It is important to acknowledge that every individual may respond differently
The recent shift towards remote healthcare management has prompted a reevaluation of traditional in-person follow-up practices for patients with axial spondyloarthritis (axSpA). A randomized trial presented at the European Alliance of Associations for Rheumatology (EULAR) annual meeting compared various follow-up approaches to determine their impact on patient outcomes and resource utilization. The results of the
